TGFB1 and myeloid sarcoma: In the present study, estimating the efficacy of ETA for the treatment of the prominent clinical features of MS and its related complications by observing its ability to attenuate the NF-κB/TNF-α/TGF-β1 signaling pathway activity and adipocyte dysfunction is a novel mode of action of ETA for the treatment of MS, compared with previous studies that have investigated TNF-α blockade in MS25.